{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:23:06Z","timestamp":1793866986097,"version":"4.6.1"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["AP1144791"],"award-info":[{"award-number":["AP1144791"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Precursor messenger RNA (pre-mRNA) splicing is a fundamental step in eukaryotic gene expression that systematically removes non-coding regions (introns) and ligates coding regions (exons) into a continuous message (mature mRNA). This process is highly regulated and can be highly flexible through a process known as alternative splicing, which allows for several transcripts to arise from a single gene, thereby greatly increasing genetic plasticity and the diversity of proteome. Alternative splicing is particularly prevalent in neuronal cells, where the splicing patterns are continuously changing to maintain cellular homeostasis and promote neurogenesis, migration and synaptic function. The continuous changes in splicing patterns and a high demand on many<jats:italic>cis-<\/jats:italic>and<jats:italic>trans-<\/jats:italic>splicing factors contribute to the susceptibility of neuronal tissues to splicing defects. The resultant neurodegenerative diseases are a large group of disorders defined by a gradual loss of neurons and a progressive impairment in neuronal function. Several of the most common neurodegenerative diseases involve some form of splicing defect(s), such as Alzheimer\u2019s disease, Parkinson\u2019s disease and spinal muscular atrophy. Our growing understanding of RNA splicing has led to the explosion of research in the field of splice-switching antisense oligonucleotide therapeutics. Here we review our current understanding of the effects alternative splicing has on neuronal differentiation, neuronal migration, synaptic maturation and regulation, as well as the impact on neurodegenerative diseases. We will also review the current landscape of splice-switching antisense oligonucleotides as a therapeutic strategy for a number of common neurodegenerative disorders.<\/jats:p>","DOI":"10.1186\/s40035-021-00240-7","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T10:03:03Z","timestamp":1621504983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies"],"prefix":"10.1186","volume":"10","author":[{"given":"Dunhui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig Stewart","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Louis","family":"Mastaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve Donald","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-2303","authenticated-orcid":false,"given":"May Thandar","family":"Aung-Htut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"240_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJ, van Roon-Mom WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Del Rev. 2015;87:90\u2013103.","journal-title":"Adv Drug Del Rev."},{"issue":"2","key":"240_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nm.3457","volume":"20","author":"JL Guo","year":"2014","unstructured":"Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med. 2014;20(2):130\u20138.","journal-title":"Nat Med."},{"issue":"2","key":"240_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/35039051","volume":"1","author":"JF Gusella","year":"2000","unstructured":"Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci. 2000;1(2):109\u201315.","journal-title":"Nat Rev Neurosci."},{"issue":"5","key":"240_CR4","doi-asserted-by":"publisher","first-page":"1012.e11","DOI":"10.1016\/j.neurobiolaging.2011.10.030","volume":"33","author":"JD Mills","year":"2012","unstructured":"Mills JD, Janitz M. Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases. Neurobiol Aging. 2012;33(5):1012.e11\u201324.","journal-title":"Neurobiol Aging"},{"issue":"5575","key":"240_CR5","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1126\/science.1067122","volume":"296","author":"JP Taylor","year":"2002","unstructured":"Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296(5575):1991\u20135.","journal-title":"Science."},{"key":"240_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.pathol.1.110304.100113","volume":"1","author":"DM Skovronsky","year":"2006","unstructured":"Skovronsky DM, Lee VMY, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis. 2006;1:151\u201370.","journal-title":"Annu Rev Pathol Mech Dis."},{"issue":"7","key":"240_CR7","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/nm1066","volume":"10","author":"CA Ross","year":"2004","unstructured":"Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(7):S10\u20137.","journal-title":"Nat Med."},{"issue":"1","key":"240_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-017-0077-5","volume":"6","author":"P Sweeney","year":"2017","unstructured":"Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6(1):1\u201313.","journal-title":"Transl Neurodegener."},{"key":"240_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fphys.2015.00277","volume":"6","author":"R Zeineddine","year":"2015","unstructured":"Zeineddine R, Yerbury JJ. The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases. Front Physiol. 2015;6:277.","journal-title":"Front Physiol."},{"issue":"12","key":"240_CR10","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1074\/jbc.R800041200","volume":"284","author":"HY Zoghbi","year":"2009","unstructured":"Zoghbi HY, Orr HT. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem. 2009;284(12):7425\u20139.","journal-title":"J Biol Chem."},{"issue":"6194","key":"240_CR11","doi-asserted-by":"publisher","first-page":"1251788","DOI":"10.1126\/science.1251788","volume":"345","author":"Consortium IWGS","year":"2014","unstructured":"Consortium IWGS. A chromosome-based draft sequence of the hexaploid bread wheat (Triticum aestivum) genome. Science. 2014;345(6194):1251788.","journal-title":"Science"},{"issue":"3","key":"240_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2014-15-3-r59","volume":"15","author":"DB Neale","year":"2014","unstructured":"Neale DB, Wegrzyn JL, Stevens KA, Zimin AV, Puiu D, Crepeau MW, et al. Decoding the massive genome of loblolly pine using haploid DNA and novel assembly strategies. Genome Biol. 2014;15(3):1\u201313.","journal-title":"Genome Biol."},{"issue":"5","key":"240_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrg2776","volume":"11","author":"H Keren","year":"2010","unstructured":"Keren H, Lev-Maor G, Ast G. Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet. 2010;11(5):345\u201355.","journal-title":"Nat Rev Genet."},{"issue":"1","key":"240_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2012.07.083","volume":"514","author":"O Kelemen","year":"2013","unstructured":"Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, et al. Function of alternative splicing. Gene. 2013;514(1):1\u201330.","journal-title":"Gene."},{"issue":"3","key":"240_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/bfgp\/elr020","volume":"10","author":"AG Douglas","year":"2011","unstructured":"Douglas AG, Wood MJ. RNA splicing: disease and therapy. Brief Funct Genomics. 2011;10(3):151\u201364.","journal-title":"Brief Funct Genomics."},{"key":"240_CR16","doi-asserted-by":"crossref","unstructured":"Sperling R. The nuts and bolts of the endogenous spliceosome. Wiley Interdiscip Rev RNA. 2017;8(1):e1377.","DOI":"10.1002\/wrna.1377"},{"issue":"1","key":"240_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ceb.2009.01.003","volume":"21","author":"JP Staley","year":"2009","unstructured":"Staley JP, Woolford JL Jr. Assembly of ribosomes and spliceosomes: complex ribonucleoprotein machines. Curr Opin Cell Biol. 2009;21(1):109\u201318.","journal-title":"Curr Opin Cell Biol."},{"issue":"7","key":"240_CR18","doi-asserted-by":"publisher","first-page":"a003707","DOI":"10.1101\/cshperspect.a003707","volume":"3","author":"CL Will","year":"2011","unstructured":"Will CL, L\u00fchrmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol. 2011;3(7):a003707.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"240_CR19","unstructured":"Pitout I. Modulation of modifiers of pre-mRNA splicing: a therapeutic strategy for amenable inherited diseases. PhD thesis,.\u00a0Perth, Australia: Murdoch University; 2018."},{"issue":"2","key":"240_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/path.2649","volume":"220","author":"AJ Ward","year":"2010","unstructured":"Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol. 2010;220(2):152\u201363.","journal-title":"J Pathol."},{"issue":"12","key":"240_CR21","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.15252\/embr.201541116","volume":"16","author":"E Daguenet","year":"2015","unstructured":"Daguenet E, Dujardin G, Valc\u00e1rcel J. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep. 2015;16(12):1640\u201355.","journal-title":"EMBO Rep."},{"issue":"7","key":"240_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrm.2017.27","volume":"18","author":"FE Baralle","year":"2017","unstructured":"Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18(7):437.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"240_CR23","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.2741\/3884","volume":"17","author":"AZ Kalea","year":"2011","unstructured":"Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front Biosci. 2011;17:2756\u201370.","journal-title":"Front Biosci."},{"issue":"11","key":"240_CR24","doi-asserted-by":"publisher","first-page":"e78267","DOI":"10.1371\/journal.pone.0078267","volume":"8","author":"J Jules","year":"2013","unstructured":"Jules J, Maiguel D, Hudson BI. Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLoS One. 2013;8(11):e78267.","journal-title":"PLoS One."},{"issue":"1","key":"240_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neulet.2004.09.059","volume":"373","author":"Q Ding","year":"2004","unstructured":"Ding Q, Keller JN. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci Lett. 2004;373(1):67\u201372.","journal-title":"Neurosci Lett."},{"issue":"1","key":"240_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/wrna.1140","volume":"4","author":"L De Conti","year":"2013","unstructured":"De Conti L, Baralle M, Buratti E. Exon and intron definition in pre-mRNA splicing. Wiley Interdiscip Rev RNA. 2013;4(1):49\u201360.","journal-title":"Wiley Interdiscip Rev RNA."},{"issue":"9","key":"240_CR27","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1093\/nar\/gkr1289","volume":"40","author":"C Sumanasekera","year":"2012","unstructured":"Sumanasekera C, Kelemen O, Beullens M, Aubol BE, Adams JA, Sunkara M, et al. C6 pyridinium ceramide influences alternative pre-mRNA splicing by inhibiting protein phosphatase-1. Nucleic Acids Res. 2012;40(9):4025\u201339.","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"240_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1356-9597.2004.00709.x","volume":"9","author":"S Kondo","year":"2004","unstructured":"Kondo S, Yamamoto N, Murakami T, Okumura M, Mayeda A, Imaizumi K. Tra2\u03b2, SF2\/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA. Genes Cells. 2004;9(2):121\u201330.","journal-title":"Genes Cells."},{"issue":"1","key":"240_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbadis.2008.09.017","volume":"1792","author":"J Tazi","year":"2009","unstructured":"Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta. 2009;1792(1):14\u201326.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"240_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.tig.2011.02.004","volume":"27","author":"SM Hammond","year":"2011","unstructured":"Hammond SM, Wood MJ. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 2011;27(5):196\u2013205.","journal-title":"Trends Genet."},{"issue":"1","key":"240_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrg.2015.3","volume":"17","author":"MM Scotti","year":"2016","unstructured":"Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet. 2016;17(1):19.","journal-title":"Nat Rev Genet."},{"issue":"12","key":"240_CR32","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1016\/j.celrep.2016.02.063","volume":"14","author":"A Fiszbein","year":"2016","unstructured":"Fiszbein A, Giono LE, Quaglino A, Berardino BG, Sigaut L, Von Bilderling C, et al. Alternative splicing of G9a regulates neuronal differentiation. Cell Rep. 2016;14(12):2797\u2013808.","journal-title":"Cell Rep."},{"issue":"4","key":"240_CR33","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.neuron.2018.01.020","volume":"97","author":"M Jacko","year":"2018","unstructured":"Jacko M, Weyn-Vanhentenryck SM, Smerdon JW, Yan R, Feng H, Williams DJ, et al. Rbfox splicing factors promote neuronal maturation and axon initial segment assembly. Neuron. 2018;97(4):853\u201368. e6.","journal-title":"Neuron"},{"issue":"7","key":"240_CR34","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.bbamem.2012.09.018","volume":"1828","author":"D Lipscombe","year":"2013","unstructured":"Lipscombe D, Andrade A, Allen SE. Alternative splicing: functional diversity among voltage-gated calcium channels and behavioral consequences. Biochim Biophy Acta. 2013;1828(7):1522\u20139.","journal-title":"Biochim Biophy Acta."},{"key":"240_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.conb.2018.12.013","volume":"57","author":"D Lipscombe","year":"2019","unstructured":"Lipscombe D, Soto EJL. Alternative splicing of neuronal genes: new mechanisms and new therapies. Curr Opin Neurobiol. 2019;57:26\u201331.","journal-title":"Curr Opin Neurobiol."},{"issue":"9","key":"240_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0968-0004(96)20021-0","volume":"21","author":"RD Kornberg","year":"1996","unstructured":"Kornberg RD. RNA polymerase II transcription control. Trends Biochem Sci. 1996;21(9):325\u20136.","journal-title":"Trends Biochem Sci."},{"issue":"10","key":"240_CR37","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1261\/rna.7100104","volume":"10","author":"AR Kornblihtt","year":"2004","unstructured":"Kornblihtt AR, de la Mata M, Fededa JP, Munoz MJ, Nogues G. Multiple links between transcription and splicing. RNA. 2004;10(10):1489\u201398.","journal-title":"RNA"},{"issue":"10","key":"240_CR38","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1371\/journal.pgen.0030173","volume":"3","author":"N Jelen","year":"2007","unstructured":"Jelen N, Ule J, \u017divin M, Darnell RB. Evolution of Nova-dependent splicing regulation in the brain. PLoS Genet. 2007;3(10):e173.","journal-title":"PLoS Genet."},{"issue":"3","key":"240_CR39","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0006-291X(02)00734-9","volume":"295","author":"J Kremerskothen","year":"2002","unstructured":"Kremerskothen J, Teber I, Wendholt D, Liedtke T, B\u00f6ckers TM, Barnekow A. Brain-specific splicing of \u03b1-actinin 1 (ACTN1) mRNA. Biochem Biophys Res Commun. 2002;295(3):678\u201381.","journal-title":"Biochem Biophys Res Commun."},{"issue":"5","key":"240_CR40","doi-asserted-by":"publisher","first-page":"e0125998","DOI":"10.1371\/journal.pone.0125998","volume":"10","author":"A Madgwick","year":"2015","unstructured":"Madgwick A, Fort P, Hanson PS, Thibault P, Gaudreau M-C, Lutfalla G, et al. Neural differentiation modulates the vertebrate brain specific splicing program. PLoS One. 2015;10(5):e0125998.","journal-title":"PLoS One."},{"issue":"3","key":"240_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1517\/17425255.2.3.399","volume":"2","author":"CM Turman","year":"2006","unstructured":"Turman CM, Hatley JM, Ryder DJ, Ravindranath V, Strobel HW. Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: The convolution continues. Expert Opin Drug Metab Toxicol. 2006;2(3):399\u2013418.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"240_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/978-0-387-77374-2_9","volume":"623","author":"J Ule","year":"2007","unstructured":"Ule J, Darnell RB. Functional and mechanistic insights from genome-wide studies of splicing regulation in the brain. Adv Exp Med Biol. 2007;623:148\u201360.","journal-title":"Adv Exp Med Biol."},{"key":"240_CR43","doi-asserted-by":"crossref","unstructured":"Black D, Grabowski P. Alternative pre-mRNA splicing and neuronal function. Prog Mol Subcell Biol. 2003;31:187\u2013216.","DOI":"10.1007\/978-3-662-09728-1_7"},{"issue":"3","key":"240_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.conb.2005.04.002","volume":"15","author":"D Lipscombe","year":"2005","unstructured":"Lipscombe D. Neuronal proteins custom designed by alternative splicing. Curr Opin Neurobiol. 2005;15(3):358\u201363.","journal-title":"Curr Opin Neurobiol."},{"key":"240_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mcn.2017.10.006","volume":"87","author":"RS Porter","year":"2018","unstructured":"Porter RS, Jaamour F, Iwase S. Neuron-specific alternative splicing of transcriptional machineries: Implications for neurodevelopmental disorders. Mol Cell Neurosci. 2018;87:35\u201345.","journal-title":"Mol Cell Neurosci."},{"issue":"4","key":"240_CR46","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006;26(4):1333\u201346.","journal-title":"Mol Cell Biol."},{"issue":"5","key":"240_CR47","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nrm1645","volume":"6","author":"AJ Matlin","year":"2005","unstructured":"Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005;6(5):386\u201398.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"240_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2004.10.022","volume":"344","author":"S Stamm","year":"2005","unstructured":"Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, et al. Function of alternative splicing. Gene. 2005;344:1\u201320.","journal-title":"Gene."},{"issue":"1","key":"240_CR49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev.biochem.72.121801.161720","volume":"72","author":"DL Black","year":"2003","unstructured":"Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 2003;72(1):291\u2013336.","journal-title":"Annu Rev Biochem."},{"issue":"12","key":"240_CR50","doi-asserted-by":"publisher","first-page":"e1000001","DOI":"10.1371\/journal.pbio.1000001","volume":"6","author":"EL Heinzen","year":"2008","unstructured":"Heinzen EL, Ge D, Cronin KD, Maia JM, Shianna KV, Gabriel WN, et al. Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol. 2008;6(12):e1000001.","journal-title":"PLoS Biol."},{"key":"240_CR51","doi-asserted-by":"crossref","unstructured":"Busch A, Hertel KJ. Evolution of SR protein and hnRNP splicing regulatory factors. Wiley Interdiscip Rev: RNA. 2012;3(1):1\u201312.","DOI":"10.1002\/wrna.100"},{"issue":"10","key":"240_CR52","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41593-019-0465-5","volume":"22","author":"E Furlanis","year":"2019","unstructured":"Furlanis E, Traunm\u00fcller L, Fucile G, Scheiffele P. Landscape of ribosome-engaged transcript isoforms reveals extensive neuronal-cell-class-specific alternative splicing programs. Nat Neurosci. 2019;22(10):1709\u201317.","journal-title":"Nat Neurosci."},{"issue":"5","key":"240_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrn.2016.27","volume":"17","author":"CK Vuong","year":"2016","unstructured":"Vuong CK, Black DL, Zheng S. The neurogenetics of alternative splicing. Nat Rev Neurosci. 2016;17(5):265\u201381.","journal-title":"Nat Rev Neurosci."},{"issue":"13","key":"240_CR54","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1101\/gad.1575607","volume":"21","author":"GC Coutinho-Mansfield","year":"2007","unstructured":"Coutinho-Mansfield GC, Xue Y, Zhang Y, Fu XD. PTB\/nPTB switch: a post-transcriptional mechanism for programming neuronal differentiation. Genes Dev. 2007;21(13):1573\u20137.","journal-title":"Genes Dev."},{"issue":"3","key":"240_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.molcel.2007.07.015","volume":"27","author":"EV Makeyev","year":"2007","unstructured":"Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell. 2007;27(3):435\u201348.","journal-title":"Mol Cell."},{"issue":"6","key":"240_CR56","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1002\/jcp.27563","volume":"234","author":"H Mokabber","year":"2019","unstructured":"Mokabber H, Najafzadeh N, Mohammadzadeh VM. miR-124 promotes neural differentiation in mouse bulge stem cells by repressing Ptbp1 and Sox9. J Cell Physiol. 2019;234(6):8941\u201350.","journal-title":"J Cell Physiol."},{"issue":"1","key":"240_CR57","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.celrep.2016.08.071","volume":"17","author":"JP Ling","year":"2016","unstructured":"Ling JP, Chhabra R, Merran JD, Schaughency PM, Wheelan SJ, Corden JL, et al. PTBP1 and PTBP2 repress nonconserved cryptic exons. Cell Rep. 2016;17(1):104\u201313.","journal-title":"Cell Rep."},{"issue":"7","key":"240_CR58","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1101\/gad.256115.114","volume":"29","author":"M Quesnel-Valli\u00e8res","year":"2015","unstructured":"Quesnel-Valli\u00e8res M, Irimia M, Cordes SP, Blencowe BJ. Essential roles for the splicing regulator nSR100\/SRRM4 during nervous system development. Genes Dev. 2015;29(7):746\u201359.","journal-title":"Genes Dev."},{"key":"240_CR59","doi-asserted-by":"publisher","first-page":"41130","DOI":"10.1038\/srep41130","volume":"7","author":"T Ohnishi","year":"2017","unstructured":"Ohnishi T, Shirane M, Nakayama KI. SRRM4-dependent neuron-specific alternative splicing of protrudin transcripts regulates neurite outgrowth. Sci Rep. 2017;7:41130.","journal-title":"Sci Rep."},{"issue":"7","key":"240_CR60","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.cell.2014.11.035","volume":"159","author":"M Irimia","year":"2014","unstructured":"Irimia M, Weatheritt RJ, Ellis JD, Parikshak NN, Gonatopoulos-Pournatzis T, Babor M, et al. A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell. 2014;159(7):1511\u201323.","journal-title":"Cell."},{"issue":"1","key":"240_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.molcel.2014.08.011","volume":"56","author":"B Raj","year":"2014","unstructured":"Raj B, Irimia M, Braunschweig U, Sterne-Weiler T, O\u2019Hanlon D, Lin ZY, et al. A global regulatory mechanism for activating an exon network required for neurogenesis. Mol Cell. 2014;56(1):90\u2013103.","journal-title":"Mol Cell."},{"issue":"11","key":"240_CR62","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.3390\/ijms21113941","volume":"21","author":"J Meldolesi","year":"2020","unstructured":"Meldolesi J. Alternative splicing by NOVA factors: from gene expression to cell physiology and pathology. Int J Mol Sci. 2020;21(11):3941.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"240_CR63","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.neuron.2010.05.007","volume":"66","author":"M Yano","year":"2010","unstructured":"Yano M, Hayakawa-Yano Y, Mele A, Darnell RB. Nova2 regulates neuronal migration through an RNA switch in disabled-1 signaling. Neuron. 2010;66(6):848\u201358.","journal-title":"Neuron."},{"key":"240_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fncel.2016.00166","volume":"10","author":"HH Bock","year":"2016","unstructured":"Bock HH, May P. Canonical and non-canonical Reelin signaling. Front Cell Neurosci. 2016;10:166.","journal-title":"Front Cell Neurosci."},{"issue":"4","key":"240_CR65","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1460-9568.2006.04612.x","volume":"23","author":"E F\u00f6rster","year":"2006","unstructured":"F\u00f6rster E, Jossin Y, Zhao S, Chai X, Frotscher M, Goffinet AM. Recent progress in understanding the role of Reelin in radial neuronal migration, with specific emphasis on the dentate gyrus. Eur J Neurosci. 2006;23(4):901\u20139.","journal-title":"Eur J Neurosci."},{"issue":"10","key":"240_CR66","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1111\/j.1460-9568.2004.03733.x","volume":"20","author":"CG Perez-Garcia","year":"2004","unstructured":"Perez-Garcia CG, Tissir F, Goffinet AM, Meyer G. Reelin receptors in developing laminated brain structures of mouse and human. Eur J Neurosci. 2004;20(10):2827\u201332.","journal-title":"Eur J Neurosci."},{"issue":"9","key":"240_CR67","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/j.1460-9568.2010.07222.x","volume":"31","author":"E F\u00f6rster","year":"2010","unstructured":"F\u00f6rster E, Bock HH, Herz J, Chai X, Frotscher M, Zhao S. Emerging topics in Reelin function. Eur J Neurosci. 2010;31(9):1511\u20138.","journal-title":"Eur J Neurosci."},{"issue":"11","key":"240_CR68","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nrn2237","volume":"8","author":"Q Li","year":"2007","unstructured":"Li Q, Lee JA, Black DL. Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci. 2007;8(11):819\u201331.","journal-title":"Nat Rev Neurosci."},{"key":"240_CR69","doi-asserted-by":"publisher","first-page":"e01201","DOI":"10.7554\/eLife.01201","volume":"3","author":"Q Li","year":"2014","unstructured":"Li Q, Zheng S, Han A, Lin CH, Stoilov P, Fu XD, et al. The splicing regulator PTBP2 controls a program of embryonic splicing required for neuronal maturation. Elife. 2014;3:e01201.","journal-title":"Elife."},{"issue":"7","key":"240_CR70","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/ng.841","volume":"43","author":"LT Gehman","year":"2011","unstructured":"Gehman LT, Stoilov P, Maguire J, Damianov A, Lin CH, Shiue L, et al. The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. Nat Genet. 2011;43(7):706\u201311.","journal-title":"Nat Genet."},{"issue":"5","key":"240_CR71","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1101\/gad.182477.111","volume":"26","author":"LT Gehman","year":"2012","unstructured":"Gehman LT, Meera P, Stoilov P, Shiue L, O\u2019Brien JE, Meisler MH, et al. The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function. Genes Dev. 2012;26(5):445\u201360.","journal-title":"Genes Dev."},{"issue":"1","key":"240_CR72","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuron.2015.11.025","volume":"89","author":"JA Lee","year":"2016","unstructured":"Lee JA, Damianov A, Lin CH, Fontes M, Parikshak NN, Anderson ES, et al. Cytoplasmic Rbfox1 regulates the expression of synaptic and autism-related genes. Neuron. 2016;89(1):113\u201328.","journal-title":"Neuron."},{"key":"240_CR73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fneur.2018.00295","volume":"9","author":"V Ghiglieri","year":"2018","unstructured":"Ghiglieri V, Calabrese V, Calabresi P. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration. Front Neurol. 2018;9:295.","journal-title":"Front Neurol."},{"issue":"8","key":"240_CR74","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","volume":"432","author":"X Hou","year":"2020","unstructured":"Hou X, Watzlawik JO, Fiesel FC, Springer W. Autophagy in Parkinson\u2019s disease. J Mol Biol. 2020;432(8):2651\u201372.","journal-title":"J Mol Biol."},{"key":"240_CR75","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fcell.2020.00405","volume":"8","author":"LG Soll","year":"2020","unstructured":"Soll LG, Eisen JN, Vargas KJ, Medeiros AT, Hammar KM, Morgan JR. \u03b1-Synuclein-112 impairs synaptic vesicle recycling consistent with its enhanced membrane binding properties. Front Cell Dev Biol. 2020;8:405.","journal-title":"Front Cell Dev Biol"},{"key":"240_CR76","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fnins.2018.00388","volume":"12","author":"M Vicario","year":"2018","unstructured":"Vicario M, Cieri D, Brini M, Cal\u00ec T. The close encounter between alpha-synuclein and mitochondria. Front Neurosci. 2018;12:388.","journal-title":"Front Neurosci."},{"issue":"2","key":"240_CR77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/genes9020063","volume":"9","author":"A G\u00e1mez-Valero","year":"2018","unstructured":"G\u00e1mez-Valero A, Beyer K. Alternative splicing of alpha-and beta-synuclein genes plays differential roles in synucleinopathies. Genes. 2018;9(2):63.","journal-title":"Genes."},{"issue":"1","key":"240_CR78","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13041-018-0371-x","volume":"11","author":"G Je","year":"2018","unstructured":"Je G, Guhathakurta S, Yun SP, Ko HS, Kim YS. A novel extended form of alpha-synuclein 3\u2019UTR in the human brain. Mol Brain. 2018;11(1):29.","journal-title":"Mol Brain."},{"key":"240_CR79","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fgene.2019.00584","volume":"10","author":"E Tseng","year":"2019","unstructured":"Tseng E, Rowell WJ, Glenn OC, Hon T, Barrera J, Kujawa S, et al. The landscape of SNCA transcripts across synucleinopathies: new insights from long reads sequencing analysis. Front Genet. 2019;10:584.","journal-title":"Front Genet."},{"key":"240_CR80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-020-0185-5","volume":"9","author":"S Kaji","year":"2020","unstructured":"Kaji S, Maki T, Ishimoto T, Yamakado H, Takahashi R. Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions. Transl Neurodegener. 2020;9:7.","journal-title":"Transl Neurodegener."},{"issue":"1","key":"240_CR81","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JPD-160779","volume":"6","author":"A Oueslati","year":"2016","unstructured":"Oueslati A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: What have we learned in the last decade? J Parkinsons Dis. 2016;6(1):39\u201351.","journal-title":"J Parkinsons Dis."},{"issue":"1","key":"240_CR82","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318(1):121\u201334.","journal-title":"Cell Tissue Res."},{"issue":"12","key":"240_CR83","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1021\/acschemneuro.8b00140","volume":"9","author":"RL Vinnakota","year":"2018","unstructured":"Vinnakota RL, Yedlapudi D, Manda KM, Bhamidipati K, Bommakanti KT, RangaLakshmi GS, et al. Identification of an alternatively spliced \u03b1-synuclein isoform that generates a 41-amino acid N-terminal truncated peptide, 41-syn: role in dopamine homeostasis. ACS Chem Neurosci. 2018;9(12):2948\u201358.","journal-title":"ACS Chem Neurosci."},{"key":"240_CR84","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3389\/fgene.2019.01013","volume":"10","author":"SA Krupenko","year":"2019","unstructured":"Krupenko SA, Horita DA. The role of single-nucleotide polymorphisms in the function of candidate tumor suppressor ALDH1L1. Front Genet. 2019;10:1013.","journal-title":"Front Genet."},{"issue":"7601","key":"240_CR85","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature17939","volume":"533","author":"F Soldner","year":"2016","unstructured":"Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC, Barrasa MI, et al. Parkinson-associated risk variant in distal enhancer of \u03b1-synuclein modulates target gene expression. Nature. 2016;533(7601):95\u20139.","journal-title":"Nature."},{"key":"240_CR86","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2017.04.004","volume":"154","author":"S Guhathakurta","year":"2017","unstructured":"Guhathakurta S, Bok E, Evangelista BA, Kim YS. Deregulation of \u03b1-synuclein in Parkinson\u2019s disease: Insight from epigenetic structure and transcriptional regulation of SNCA. Prog Neurobiol. 2017;154:21\u201336.","journal-title":"Prog Neurobiol."},{"issue":"1","key":"240_CR87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10048-010-0263-4","volume":"12","author":"JJ McCarthy","year":"2011","unstructured":"McCarthy JJ, Linnertz C, Saucier L, Burke JR, Hulette CM, Welsh-Bohmer KA, et al. The effect of SNCA 3\u2019 region on the levels of SNCA-112 splicing variant. Neurogenetics. 2011;12(1):59\u201364.","journal-title":"Neurogenetics."},{"key":"240_CR88","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fnagi.2017.00198","volume":"9","author":"CLC Camp\u00ealo","year":"2017","unstructured":"Camp\u00ealo CLC, Cagni FC, de Siqueira FD, Oliveira LG Jr, Silva-Neto AB, Mac\u00eado PT, et al. Variants in SNCA gene are associated with Parkinson\u2019s disease risk and cognitive symptoms in a Brazilian sample. Front Aging Neurosci. 2017;9:198.","journal-title":"Front Aging Neurosci."},{"issue":"4","key":"240_CR89","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/mgg3.407","volume":"6","author":"ES Barrie","year":"2018","unstructured":"Barrie ES, Lee SH, Frater JT, Kataki M, Scharre DW, Sadee W. Alpha-synuclein mRNA isoform formation and translation affected by polymorphism in the human SNCA 3\u2019UTR. Mol Genet Genomic Med. 2018;6(4):565\u201374.","journal-title":"Mol Genet Genomic Med."},{"key":"240_CR90","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.gde.2017.01.014","volume":"44","author":"O Chiba-Falek","year":"2017","unstructured":"Chiba-Falek O. Structural variants in SNCA gene and the implication to synucleinopathies. Curr Opin Genet Dev. 2017;44:110\u20136.","journal-title":"Curr Opin Genet Dev."},{"issue":"7","key":"240_CR91","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/jnr.21270","volume":"85","author":"K Beyer","year":"2007","unstructured":"Beyer K, Humbert J, Ferrer A, Lao JI, Latorre P, Lopez D, et al. A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging. J Neurosci Res. 2007;85(7):1538\u201346.","journal-title":"J Neurosci Res."},{"issue":"2","key":"240_CR92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16(2):97\u2013107.","journal-title":"Nat Rev Neurol."},{"issue":"4","key":"240_CR93","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10048-015-0449-x","volume":"16","author":"V La Cognata","year":"2015","unstructured":"La Cognata V, D\u2019Agata V, Cavalcanti F, Cavallaro S. Splicing: is there an alternative contribution to Parkinson\u2019s disease? Neurogenetics. 2015;16(4):245\u201363.","journal-title":"Neurogenetics."},{"key":"240_CR94","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.biopha.2018.12.101","volume":"111","author":"SH Tan","year":"2019","unstructured":"Tan SH, Karri V, Tay NWR, Chang KH, Ah HY, Ng PQ, et al. Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer\u2019s disease, Parkinson\u2019s disease. Biomed Pharmacother. 2019;111:765\u201377.","journal-title":"Biomed Pharmacother"},{"key":"240_CR95","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","volume":"7","author":"X Du","year":"2018","unstructured":"Du X, Wang X, Geng M. Alzheimer\u2019s disease hypothesis and related therapies. Transl Neurodegener. 2018;7:2.","journal-title":"Transl Neurodegener."},{"key":"240_CR96","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nbd.2017.05.003","volume":"105","author":"MA Sealey","year":"2017","unstructured":"Sealey MA, Vourkou E, Cowan CM, Bossing T, Quraishe S, Grammenoudi S, et al. Distinct phenotypes of three-repeat and four-repeat human tau in a transgenic model of tauopathy. Neurobiol Dis. 2017;105:74\u201383.","journal-title":"Neurobiol Dis."},{"key":"240_CR97","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1749-6632.1996.tb34407.x","volume":"777","author":"EM Mandelkow","year":"1996","unstructured":"Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, et al. Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci. 1996;777:96\u2013106.","journal-title":"Ann N Y Acad Sci."},{"key":"240_CR98","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fncel.2018.00338","volume":"12","author":"AD Alonso","year":"2018","unstructured":"Alonso AD, Cohen LS, Corbo C, Morozova V, ElIdrissi A, Phillips G, et al. Hyperphosphorylation of Tau associates with changes in its function beyond microtubule stability. Front Cell Neurosci. 2018;12:338.","journal-title":"Front Cell Neurosci."},{"issue":"7","key":"240_CR99","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","volume":"99","author":"KH Strang","year":"2019","unstructured":"Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019;99(7):912\u201328.","journal-title":"Lab Invest."},{"issue":"2","key":"240_CR100","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12264-013-1411-2","volume":"30","author":"W Qian","year":"2014","unstructured":"Qian W, Liu F. Regulation of alternative splicing of tau exon 10. Neurosci Bull. 2014;30(2):367\u201377.","journal-title":"Neurosci Bull."},{"issue":"3","key":"240_CR101","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41593-020-0599-5","volume":"23","author":"R Sims","year":"2020","unstructured":"Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer\u2019s disease. Nat Neurosci. 2020;23(3):311\u201322.","journal-title":"Nat Neurosci."},{"issue":"10043","key":"240_CR102","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388(10043):505\u201317.","journal-title":"Lancet."},{"issue":"7","key":"240_CR103","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.3390\/ijms21072381","volume":"21","author":"CL Gan","year":"2020","unstructured":"Gan CL, Zhang T, Lee TH. The genetics of Alzheimer\u2019s disease in the Chinese population. Int J Mol Sci. 2020;21(7):2381.","journal-title":"Int J Mol Sci"},{"key":"240_CR104","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fnmol.2017.00294","volume":"10","author":"X Wang","year":"2017","unstructured":"Wang X, Zhou X, Li G, Zhang Y, Wu Y, Song W. Modifications and trafficking of APP in the pathogenesis of Alzheimer\u2019s disease. Front Mol Neurosci. 2017;10:294.","journal-title":"Front Mol Neurosci."},{"issue":"11","key":"240_CR105","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41380-019-0410-8","volume":"25","author":"C Arber","year":"2020","unstructured":"Arber C, Toombs J, Lovejoy C, Ryan NS, Paterson RW, Willumsen N, et al. Familial Alzheimer\u2019s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol Psychiatry. 2020;25(11):2919\u201331.","journal-title":"Mol Psychiatry."},{"issue":"4","key":"240_CR106","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1073\/pnas.1619574114","volume":"114","author":"RJ Kelleher 3rd","year":"2017","unstructured":"Kelleher RJ 3rd, Shen J. Presenilin-1 mutations and Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2017;114(4):629\u201331.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"240_CR107","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1073\/pnas.1618657114","volume":"114","author":"L Sun","year":"2017","unstructured":"Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase. Proc Natl Acad Sci U S A. 2017;114(4):E476\u2013e85.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"240_CR108","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jalz.2018.12.010","volume":"15","author":"L Ramirez Aguilar","year":"2019","unstructured":"Ramirez Aguilar L, Acosta-Uribe J, Giraldo MM, Moreno S, Baena A, Alzate D, et al. Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr). Alzheimers Dement. 2019;15(5):709\u201319.","journal-title":"Alzheimers Dement."},{"issue":"9","key":"240_CR109","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/mp.2015.100","volume":"20","author":"A Rovelet-Lecrux","year":"2015","unstructured":"Rovelet-Lecrux A, Charbonnier C, Wallon D, Nicolas G, Seaman MN, Pottier C, et al. De novo deleterious genetic variations target a biological network centered on A\u03b2 peptide in early-onset Alzheimer disease. Mol Psychiatry. 2015;20(9):1046\u201356.","journal-title":"Mol Psychiatry."},{"key":"240_CR110","doi-asserted-by":"publisher","first-page":"292.e7","DOI":"10.1016\/j.neurobiolaging.2018.04.015","volume":"69","author":"F Perrone","year":"2018","unstructured":"Perrone F, Cacace R, Van Mossevelde S, Van den Bossche T, De Deyn PP, Cras P, et al. Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. Neurobiol Aging. 2018;69:292.e7\u201392.e14.","journal-title":"Neurobiol Aging"},{"issue":"Pt 4","key":"240_CR111","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/brain\/awq033","volume":"133","author":"S Jayadev","year":"2010","unstructured":"Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, et al. Alzheimer\u2019s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(Pt 4):1143\u201354.","journal-title":"Brain."},{"issue":"4","key":"240_CR112","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/acn3.755","volume":"6","author":"JE Braggin","year":"2019","unstructured":"Braggin JE, Bucks SA, Course MM, Smith CL, Sopher B, Osnis L, et al. Alternative splicing in a presenilin 2 variant associated with Alzheimer disease. Ann Clin Transl Neurol. 2019;6(4):762\u201377.","journal-title":"Ann Clin Transl Neurol."},{"issue":"2","key":"240_CR113","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3233\/JAD-150678","volume":"52","author":"E Ebrahimie","year":"2016","unstructured":"Ebrahimie E, Moussavi Nik SH, Newman M, Van Der Hoek M, Lardelli M. The zebrafish equivalent of Alzheimer\u2019s disease-associated PRESENILIN isoform PS2V regulates inflammatory and other responses to hypoxic stress. J Alzheimers Dis. 2016;52(2):581\u2013608.","journal-title":"J Alzheimers Dis."},{"issue":"13","key":"240_CR114","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1093\/hmg\/ddv110","volume":"24","author":"SH Moussavi Nik","year":"2015","unstructured":"Moussavi Nik SH, Newman M, Wilson L, Ebrahimie E, Wells S, Musgrave I, et al. Alzheimer\u2019s disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of \u03b3-secretase activity. Hum Mol Genet. 2015;24(13):3662\u201378.","journal-title":"Hum Mol Genet."},{"issue":"1","key":"240_CR115","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13024-020-0358-9","volume":"15","author":"T Williams","year":"2020","unstructured":"Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer\u2019s disease. Mol Neurodegener. 2020;15(1):8.","journal-title":"Mol Neurodegener."},{"issue":"1","key":"240_CR116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","volume":"17","author":"M Safieh","year":"2019","unstructured":"Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease. BMC Med. 2019;17(1):64.","journal-title":"BMC Med."},{"issue":"6","key":"240_CR117","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2174\/1567205010666131119232444","volume":"11","author":"M Gilat-Frenkel","year":"2014","unstructured":"Gilat-Frenkel M, Boehm-Cagan A, Liraz O, Xian X, Herz J, Michaelson DM. Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo. Curr Alzheimer Res. 2014;11(6):549\u201357.","journal-title":"Curr Alzheimer Res."},{"key":"240_CR118","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fnmol.2020.00144","volume":"13","author":"CM Gallo","year":"2020","unstructured":"Gallo CM, Ho A, Beffert U. ApoER2: functional tuning through splicing. Front Mol Neurosci. 2020;13:144.","journal-title":"Front Mol Neurosci."},{"issue":"353","key":"240_CR119","doi-asserted-by":"publisher","first-page":"ra113","DOI":"10.1126\/scisignal.2005438","volume":"7","author":"CR Wasser","year":"2014","unstructured":"Wasser CR, Masiulis I, Durakoglugil MS, Lane-Donovan C, Xian X, Beffert U, et al. Differential splicing and glycosylation of Apoer2 alters synaptic plasticity and fear learning. Sci Signal. 2014;7(353):ra113.","journal-title":"Sci Signal"},{"issue":"10","key":"240_CR120","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1001\/archneur.1997.00550220050013","volume":"54","author":"RH Brown Jr","year":"1997","unstructured":"Brown RH Jr. Amyotrophic lateral sclerosis. Insights from genetics. Arch Neurol. 1997;54(10):1246\u201350.","journal-title":"Arch Neurol."},{"issue":"5","key":"240_CR121","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-020-02203-0","volume":"140","author":"A Bampton","year":"2020","unstructured":"Bampton A, Gittings LM, Fratta P, Lashley T, Gatt A. The role of hnRNPs in frontotemporal dementia and amyotrophic lateral sclerosis. Acta Neuropathol. 2020;140(5):599\u2013623.","journal-title":"Acta Neuropathol."},{"key":"240_CR122","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnins.2020.00042","volume":"14","author":"YA Abramzon","year":"2020","unstructured":"Abramzon YA, Fratta P, Traynor BJ, Chia R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2020;14:42.","journal-title":"Front Neurosci."},{"issue":"4","key":"240_CR123","doi-asserted-by":"publisher","first-page":"a024224","DOI":"10.1101\/cshperspect.a024224","volume":"8","author":"TF Gendron","year":"2018","unstructured":"Gendron TF, Petrucelli L. Disease mechanisms of C9ORF72 repeat expansions. Cold Spring Harb Perspect Med. 2018;8(4):a024224.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"240_CR124","doi-asserted-by":"publisher","first-page":"562758","DOI":"10.3389\/fgene.2020.562758","volume":"11","author":"Q Yang","year":"2020","unstructured":"Yang Q, Jiao B, Shen L. The development of C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia disorders. Front Genet. 2020;11:562758.","journal-title":"Front Genet."},{"key":"240_CR125","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fncel.2017.00195","volume":"11","author":"HV Barker","year":"2017","unstructured":"Barker HV, Niblock M, Lee YB, Shaw CE, Gallo JM. RNA misprocessing in C9orf72-linked neurodegeneration. Front Cell Neurosci. 2017;11:195.","journal-title":"Front Cell Neurosci."},{"key":"240_CR126","doi-asserted-by":"crossref","unstructured":"Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. 2016;5:e17820.","DOI":"10.7554\/eLife.17820"},{"issue":"5","key":"240_CR127","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/brain\/awy062","volume":"141","author":"JE Deshaies","year":"2018","unstructured":"Deshaies JE, Shkreta L, Moszczynski AJ, Sidib\u00e9 H, Semmler S, Fouillen A, et al. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain. 2018;141(5):1320\u201333.","journal-title":"Brain."},{"key":"240_CR128","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3389\/fgene.2018.00712","volume":"9","author":"Z Butti","year":"2018","unstructured":"Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front Genet. 2018;9:712.","journal-title":"Front Genet."},{"issue":"4","key":"240_CR129","doi-asserted-by":"publisher","first-page":"e00669","DOI":"10.1002\/brb3.669","volume":"7","author":"K Tripolszki","year":"2017","unstructured":"Tripolszki K, T\u00f6r\u00f6k D, Gouden\u00e8ge D, Farkas K, Sul\u00e1k A, T\u00f6r\u00f6k N, et al. High-throughput sequencing revealed a novel SETX mutation in a Hungarian patient with amyotrophic lateral sclerosis. Brain Behav. 2017;7(4):e00669.","journal-title":"Brain Behav."},{"issue":"7295","key":"240_CR130","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature08971","volume":"465","author":"H Maruyama","year":"2010","unstructured":"Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223\u20136.","journal-title":"Nature."},{"issue":"1","key":"240_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10571-019-00717-0","volume":"40","author":"B Perrone","year":"2020","unstructured":"Perrone B, La Cognata V, Sprovieri T, Ungaro C, Conforti FL, And\u00f2 S, et al. Alternative splicing of ALS genes: misregulation and potential therapies. Cell Mol Neurobiol. 2020;40(1):1\u201314.","journal-title":"Cell Mol Neurobiol."},{"issue":"6","key":"240_CR132","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol."},{"issue":"3","key":"240_CR133","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","volume":"85","author":"TW Prior","year":"2009","unstructured":"Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85(3):408\u201313.","journal-title":"Am J Hum Genet."},{"issue":"3","key":"240_CR134","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0959-437X(02)00303-9","volume":"12","author":"SA Slaugenhaupt","year":"2002","unstructured":"Slaugenhaupt SA, Gusella JF. Familial dysautonomia. Curr Opin Genet Dev. 2002;12(3):307\u201311.","journal-title":"Curr Opin Genet Dev."},{"issue":"3","key":"240_CR135","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1086\/318808","volume":"68","author":"SL Anderson","year":"2001","unstructured":"Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, et al. Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet. 2001;68(3):753\u20138.","journal-title":"Am J Hum Genet."},{"key":"240_CR136","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-genet-112414-054639","volume":"49","author":"F He","year":"2015","unstructured":"He F, Jacobson A. Nonsense-mediated mRNA decay: degradation of defective transcripts is only part of the story. Annu Rev Genet. 2015;49:339\u201366.","journal-title":"Annu Rev Genet."},{"issue":"4","key":"240_CR137","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1590\/1678-4685-gmb-2015-0335","volume":"39","author":"P Dietrich","year":"2016","unstructured":"Dietrich P, Dragatsis I. Familial dysautonomia: mechanisms and models. Genet Mol Biol. 2016;39(4):497\u2013514.","journal-title":"Genet Mol Biol."},{"key":"240_CR138","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-444-63233-3.00009-9","volume":"147","author":"H Paulson","year":"2018","unstructured":"Paulson H. Repeat expansion diseases. Handb Clin Neurol. 2018;147:105\u201323.","journal-title":"Handb Clin Neurol."},{"key":"240_CR139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gde.2017.01.005","volume":"44","author":"N Zhang","year":"2017","unstructured":"Zhang N, Ashizawa T. RNA toxicity and foci formation in microsatellite expansion diseases. Curr Opin Genet Dev. 2017;44:17\u201329.","journal-title":"Curr Opin Genet Dev."},{"issue":"4","key":"240_CR140","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrg2748","volume":"11","author":"AR La Spada","year":"2010","unstructured":"La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet. 2010;11(4):247\u201358.","journal-title":"Nat Rev Genet."},{"issue":"10","key":"240_CR141","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrg1691","volume":"6","author":"JR Gatchel","year":"2005","unstructured":"Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005;6(10):743\u201355.","journal-title":"Nat Rev Genet."},{"issue":"11-12","key":"240_CR142","doi-asserted-by":"publisher","first-page":"194405","DOI":"10.1016\/j.bbagrm.2019.07.006","volume":"1862","author":"MA Hale","year":"2019","unstructured":"Hale MA, Johnson NE, Berglund JA. Repeat-associated RNA structure and aberrant splicing. Biochim Biophys Acta Gene Regul Mech. 2019;1862(11-12):194405.","journal-title":"Biochim Biophys Acta Gene Regul Mech."},{"issue":"2","key":"240_CR143","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JHD-180292","volume":"7","author":"L Romo","year":"2018","unstructured":"Romo L, Mohn ES, Aronin N. A fresh look at Huntingtin mRNA processing in Huntington\u2019s disease. J Huntingtons Dis. 2018;7(2):101\u20138.","journal-title":"J Huntingtons Dis."},{"issue":"5","key":"240_CR144","doi-asserted-by":"publisher","first-page":"e1594","DOI":"10.1002\/wrna.1594","volume":"11","author":"AM Quemener","year":"2020","unstructured":"Quemener AM, Bachelot L, Forestier A, Donnou-Fournet E, Gilot D, Galibert MD. The powerful world of antisense oligonucleotides: From bench to bedside. Wiley Interdiscip Rev RNA. 2020;11(5):e1594.","journal-title":"Wiley Interdiscip Rev RNA."},{"issue":"7","key":"240_CR145","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/hum.2013.234","volume":"25","author":"P Disterer","year":"2014","unstructured":"Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, et al. Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther. 2014;25(7):587\u201398.","journal-title":"Hum Gene Ther."},{"key":"240_CR146","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-0716-0243-0_15","volume":"2105","author":"C Brolin","year":"2020","unstructured":"Brolin C, Lim EWK, Nielsen PE. In vivo administration of splice switching PNAs using the mdx mouse as a model system. Methods Mol Biol. 2020;2105:241\u201350.","journal-title":"Methods Mol Biol."},{"issue":"2","key":"240_CR147","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrd3625","volume":"11","author":"R Kole","year":"2012","unstructured":"Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11(2):125\u201340.","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"240_CR148","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","volume":"39","author":"D Li","year":"2018","unstructured":"Li D, Mastaglia FL, Fletcher S, Wilton SD. Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends Pharmacol Sci. 2018;39(11):982\u201394.","journal-title":"Trends Pharmacol Sci."},{"issue":"3","key":"240_CR149","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238\u201348.","journal-title":"Nat Biotechnol."},{"issue":"1","key":"240_CR150","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1073\/pnas.75.1.280","volume":"75","author":"PC Zamecnik","year":"1978","unstructured":"Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978;75(1):280\u20134.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"20","key":"240_CR151","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.3390\/ijms20205030","volume":"20","author":"MT Aung-Htut","year":"2019","unstructured":"Aung-Htut MT, McIntosh CS, Ham KA, Pitout IL, Flynn LL, Greer K, et al. Systematic approach to developing splice modulating antisense oligonucleotides. Int J Mol Sci. 2019;20(20):5030.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"240_CR152","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/sj.mt.6300245","volume":"15","author":"S Fletcher","year":"2007","unstructured":"Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther. 2007;15(9):1587\u201392.","journal-title":"Mol Ther."},{"issue":"9-10","key":"240_CR153","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.nmd.2006.05.017","volume":"16","author":"G McClorey","year":"2006","unstructured":"McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, et al. Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord. 2006;16(9-10):583\u201390.","journal-title":"Neuromuscul Disord."},{"issue":"1","key":"240_CR154","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.mt.6300006","volume":"15","author":"PL Harding","year":"2007","unstructured":"Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD. The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther. 2007;15(1):157\u201366.","journal-title":"Mol Ther."},{"issue":"21","key":"240_CR155","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.3390\/ijms20215434","volume":"20","author":"CS McIntosh","year":"2019","unstructured":"McIntosh CS, Aung-Htut MT, Fletcher S, Wilton SD. Removal of the polyglutamine repeat of Ataxin-3 by redirecting pre-mRNA processing. Int J Mol Sci. 2019;20(21):5434.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"240_CR156","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.4049\/jimmunol.180.6.3729","volume":"180","author":"A Forsbach","year":"2008","unstructured":"Forsbach A, Nemorin JG, Montino C, M\u00fcller C, Samulowitz U, Vicari AP, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol. 2008;180(6):3729\u201338.","journal-title":"J Immunol."},{"issue":"6","key":"240_CR157","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1002\/med.21718","volume":"40","author":"D Li","year":"2020","unstructured":"Li D, Mastaglia FL, Fletcher S, Wilton SD. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson\u2019s disease in the precision medicine era. Med Res Rev. 2020;40(6):2650\u201381.","journal-title":"Med Res Rev."},{"issue":"16","key":"240_CR158","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.3390\/molecules24162922","volume":"24","author":"MT Aung-Htut","year":"2019","unstructured":"Aung-Htut MT, McIntosh CS, West KA, Fletcher S, Wilton SD. In vitro validation of phosphorodiamidate morpholino oligomers. Molecules. 2019;24(16):2922.","journal-title":"Molecules"},{"issue":"7","key":"240_CR159","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/156802607780487740","volume":"7","author":"JE Summerton","year":"2007","unstructured":"Summerton JE. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem. 2007;7(7):651\u201360.","journal-title":"Curr Top Med Chem."},{"issue":"5","key":"240_CR160","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/1389201043376706","volume":"5","author":"V Arora","year":"2004","unstructured":"Arora V, Devi GR, Iversen PL. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol. 2004;5(5):431\u20139.","journal-title":"Curr Pharm Biotechnol."},{"issue":"3","key":"240_CR161","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7(3):187\u201395.","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"240_CR162","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: Golodirsen for duchenne muscular dystrophy. Nucleic Acid Ther. 2020;30(2):67\u201370.","DOI":"10.1089\/nat.2020.0845"},{"issue":"8","key":"240_CR163","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T. Golodirsen for Duchenne muscular dystrophy. Drugs Today (Barc). 2020;56(8):491\u2013504.","journal-title":"Drugs Today (Barc)."},{"issue":"26","key":"240_CR164","doi-asserted-by":"publisher","first-page":"e15858","DOI":"10.1097\/MD.0000000000015858","volume":"98","author":"LN Alfano","year":"2019","unstructured":"Alfano LN, Charleston JS, Connolly AM, Cripe L, Donoghue C, Dracker R, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (Baltimore). 2019;98(26):e15858.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"240_CR165","first-page":"54","volume":"49","author":"AH Beggs","year":"1991","unstructured":"Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet. 1991;49(1):54\u201367.","journal-title":"Am J Hum Genet."},{"issue":"15","key":"240_CR166","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24(15):1634\u201344.","journal-title":"Genes Dev."},{"issue":"3","key":"240_CR167","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","volume":"59","author":"A Anna","year":"2018","unstructured":"Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet. 2018;59(3):253\u201368.","journal-title":"J Appl Genet."},{"issue":"18","key":"240_CR168","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med."},{"issue":"12","key":"240_CR169","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/13543784.2020.1837110","volume":"29","author":"MC Masten","year":"2020","unstructured":"Masten MC, Mink JW, Augustine EF. Batten disease: an expert update on agents in preclinical and clinical trials. Expert Opin Investig Drugs. 2020;29(12):1317\u201322.","journal-title":"Expert Opin Investig Drugs."},{"issue":"6","key":"240_CR170","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/nat.2019.29003.aar","volume":"29","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus A, Watts JK. The Munich meeting: medical maturation, more mechanisms, and milasen. Nucleic Acid Ther. 2019;29(6):302\u20134.","journal-title":"Nucleic Acid Ther."},{"issue":"19","key":"240_CR171","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/hmg\/ddz126","volume":"28","author":"JA Korecka","year":"2019","unstructured":"Korecka JA, Thomas R, Christensen DP, Hinrich AJ, Ferrari EJ, Levy SA, et al. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson\u2019s disease patient fibroblasts. Hum Mol Genet. 2019;28(19):3232\u201343.","journal-title":"Hum Mol Genet."},{"issue":"1","key":"240_CR172","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.stemcr.2018.11.021","volume":"12","author":"JA Korecka","year":"2019","unstructured":"Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, et al. Neurite collapse and altered ER Ca (2+) control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation. Stem Cell Reports. 2019;12(1):29\u201341.","journal-title":"Stem Cell Reports."},{"key":"240_CR173","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.omtn.2020.06.027","volume":"21","author":"JA Korecka","year":"2020","unstructured":"Korecka JA, Thomas R, Hinrich AJ, Moskites AM, Macbain ZK, Hallett PJ, et al. Splice-switching antisense oligonucleotides reduce LRRK2 kinase activity in human LRRK2 transgenic mice. Mol Ther Nucleic Acids. 2020;21:623\u201335.","journal-title":"Mol Ther Nucleic Acids."},{"key":"240_CR174","first-page":"1819209","volume":"2016","author":"W Haylett","year":"2016","unstructured":"Haylett W, Swart C, van der Westhuizen F, van Dyk H, van der Merwe L, van der Merwe C, et al. Altered mitochondrial respiration and other features of mitochondrial function in Parkin-mutant fibroblasts from Parkinson\u2019s disease patients. Parkinsons Dis. 2016;2016:1819209.","journal-title":"Parkinsons Dis."},{"issue":"1","key":"240_CR175","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.bbrc.2009.11.141","volume":"391","author":"H Asai","year":"2010","unstructured":"Asai H, Hirano M, Kiriyama T, Ikeda M, Ueno S. Naturally- and experimentally-designed restorations of the Parkin gene deficit in autosomal recessive juvenile parkinsonism. Biochem Biophys Res Commun. 2010;391(1):800\u20135.","journal-title":"Biochem Biophys Res Commun."},{"issue":"6139","key":"240_CR176","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1126\/science.1237908","volume":"340","author":"JF Trempe","year":"2013","unstructured":"Trempe JF, Sauv\u00e9 V, Grenier K, Seirafi M, Tang MY, M\u00e9nade M, et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science. 2013;340(6139):1451\u20135.","journal-title":"Science."},{"issue":"19","key":"240_CR177","doi-asserted-by":"publisher","first-page":"7282","DOI":"10.3390\/ijms21197282","volume":"21","author":"D Li","year":"2020","unstructured":"Li D, Aung-Htut MT, Ham KA, Fletcher S, Wilton SD. A splice intervention therapy for autosomal recessive juvenile Parkinson\u2019s disease arising from Parkin mutations. Int J Mol Sci. 2020;21(19):7282.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"240_CR178","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1038\/s41598-020-63412-x","volume":"10","author":"TJ Stevenson","year":"2020","unstructured":"Stevenson TJ, Murray HC, Turner C, Faull RLM, Dieriks BV, Curtis MA. \u03b1-synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory nucleus of the Parkinson\u2019s disease olfactory bulb. Sci Rep. 2020;10(1):6682.","journal-title":"Sci Rep."},{"issue":"10","key":"240_CR179","doi-asserted-by":"publisher","first-page":"a024331","DOI":"10.1101\/cshperspect.a024331","volume":"7","author":"G Gallardo","year":"2017","unstructured":"Gallardo G, Holtzman DM. Antibody therapeutics targeting A\u03b2 and Tau. Cold Spring Harb Perspect Med. 2017;7(10):a024331.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"16","key":"240_CR180","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.7150\/thno.21529","volume":"7","author":"M Chakravarthy","year":"2017","unstructured":"Chakravarthy M, Chen S, Dodd PR, Veedu RN. Nucleic acid-based theranostics for tackling Alzheimer\u2019s disease. Theranostics. 2017;7(16):3933\u201347.","journal-title":"Theranostics."},{"issue":"6","key":"240_CR181","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","volume":"26","author":"JL Chang","year":"2018","unstructured":"Chang JL, Hinrich AJ, Roman B, Norrbom M, Rigo F, Marr RA, et al. Targeting amyloid-\u03b2 precursor protein, app, splicing with antisense oligonucleotides reduces toxic amyloid-\u03b2 production. Mol Ther. 2018;26(6):1539\u201351.","journal-title":"Mol Ther."},{"issue":"9","key":"240_CR182","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/genes10090705","volume":"10","author":"M Chakravarthy","year":"2019","unstructured":"Chakravarthy M, Veedu RN. BACE1 inhibition using 2\u2019-OMePS steric blocking antisense oligonucleotides. Genes (Basel). 2019;10(9):705.","journal-title":"Genes (Basel)"},{"issue":"3","key":"240_CR183","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4103\/1673-5374.179044","volume":"11","author":"L Wu","year":"2016","unstructured":"Wu L, Zhao L. ApoE2 and Alzheimer\u2019s disease: time to take a closer look. Neural Regen Res. 2016;11(3):412\u20133.","journal-title":"Neural Regen Res."},{"issue":"5","key":"240_CR184","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"TV Huynh","year":"2017","unstructured":"Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis. Neuron. 2017;96(5):1013\u201323.e4.","journal-title":"Neuron"},{"issue":"4","key":"240_CR185","doi-asserted-by":"publisher","first-page":"328","DOI":"10.15252\/emmm.201505846","volume":"8","author":"AJ Hinrich","year":"2016","unstructured":"Hinrich AJ, Jodelka FM, Chang JL, Brutman D, Bruno AM, Briggs CA, et al. Therapeutic correction of ApoER2 splicing in Alzheimer\u2019s disease mice using antisense oligonucleotides. EMBO Mol Med. 2016;8(4):328\u201345.","journal-title":"EMBO Mol Med."},{"issue":"15 Supplement","key":"240_CR186","doi-asserted-by":"crossref","first-page":"S25.004","DOI":"10.1212\/WNL.90.15_supplement.S25.004","volume":"90","author":"L Hayes","year":"2018","unstructured":"Hayes L, Coyne A, Jafar-Nejad P, Rigo F, Rothstein J. Strand-specific antisense oligonucleotides for C9ORF72-ALS\/FTD (S25.004). Neurology. 2018;90(15 Supplement):S25.004.","journal-title":"Neurology"},{"issue":"5","key":"240_CR187","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41593-020-0619-5","volume":"23","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Jiang J, Gendron TF, McAlonis-Downes M, Jiang L, Taylor A, et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS\/FTD-causing repeat expansion in C9orf72. Nat Neurosci. 2020;23(5):615\u201324.","journal-title":"Nat Neurosci."},{"key":"240_CR188","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.omtn.2020.01.027","volume":"19","author":"SG Poplawski","year":"2020","unstructured":"Poplawski SG, Garbett KA, McMahan RL, Kordasiewicz HB, Zhao H, Kennedy AJ, et al. An antisense oligonucleotide leads to suppressed transcription of Hdac2 and long-term memory enhancement. Mol Ther Nucleic Acids. 2020;19:1399\u2013412.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"1","key":"240_CR189","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40478-017-0468-y","volume":"5","author":"KJ Rohilla","year":"2017","unstructured":"Rohilla KJ, Gagnon KT. RNA biology of disease-associated microsatellite repeat expansions. Acta Neuropathol Commun. 2017;5(1):63.","journal-title":"Acta Neuropathol Commun."},{"key":"240_CR190","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","volume":"8","author":"LJA Toonen","year":"2017","unstructured":"Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC. Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol Ther Nucleic Acids. 2017;8:232\u201342.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"2","key":"240_CR191","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2005056","volume":"383","author":"C Mueller","year":"2020","unstructured":"Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, et al. SOD1 suppression with adeno-associated virus and microrna in familial ALS. N Engl J Med. 2020;383(2):151\u20138.","journal-title":"N Engl J Med."},{"key":"240_CR192","volume-title":"Treatment for SOD1 associated disease","author":"SD Wilton","year":"2020","unstructured":"Wilton SD, Fletcher S, Flynn L, Akkari PA. Treatment for SOD1 associated disease. 2020. Publication Number: WO\/2020\/222182"}],"updated-by":[{"DOI":"10.1186\/s40035-021-00267-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000}}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-021-00240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-021-00240-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-021-00240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T07:28:25Z","timestamp":1725089305000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-021-00240-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":192,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1186\/s40035-021-00240-7","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40035-021-00267-w","asserted-by":"object"}]},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"15 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40035-021-00267-w","URL":"https:\/\/doi.org\/10.1186\/s40035-021-00267-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SDW is a consultant to Sarepta Therapeutics. He is named as an inventor on patents licensed through the University of Western Australia to Sarepta Therapeutics, and as such is entitled to milestone and royalty payments. DHL, CSM and MATH salaries are partly funded by Sarepta Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}